A phase I dose-escalation study to a predefined dose of a transforming growth factor-β1 monoclonal antibody (TβM1) in patients with metastatic cancer

Transforming growth factor β (TGF-β) plays an important role in cancer. Monoclonal antibodies (mAb) designed to specifically block the TGF-β ligands, are expected to inhibit tumor progression in patients with metastatic cancer. TβM1 is a humanized mAb optimized for neutralizing activity against TGF-...

Descripción completa

Detalles Bibliográficos
Autores principales: COHN, ALLEN, LAHN, MICHAEL M., WILLIAMS, KRISTEN E., CLEVERLY, ANN L., PITOU, CELINE, KADAM, SUNIL K., FARMEN, MARK W., DESAIAH, DURISALA, RAJU, ROBERT, CONKLING, PAUL, RICHARDS, DONALD
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2014
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4215585/
https://www.ncbi.nlm.nih.gov/pubmed/25270361
http://dx.doi.org/10.3892/ijo.2014.2679

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4215585/
https://www.ncbi.nlm.nih.gov/pubmed/25270361
http://dx.doi.org/10.3892/ijo.2014.2679

Ejemplares similares